Form 4: Contineum CSO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 4,170 shares of Class A Common Stock for a weighted average price of $15.0084 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc. (CTNM), reported a sale of company stock.
- On March 2, 2026, Lorrain sold 4,170 shares of Class A Common Stock.
- The shares were sold at a weighted average price of $15.0084 per share, with individual transaction prices ranging from $14.60 to $15.41.
- This transaction was executed under a Rule 10b5-1 trading plan established on September 23, 2025.
- Following the sale, Lorrain directly beneficially owns 151,882 shares and indirectly owns 6,842 shares through his spouse.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event because the sale was conducted under a pre-arranged 10b5-1 trading plan, which typically reflects personal financial planning rather than a change in the insider's outlook on the company's prospects.
Negatives
- An insider, the Chief Scientific Officer, sold 4,170 shares of Class A Common Stock.
Future Outlook
No specific future outlook or guidance is provided in this insider transaction report.
Industry Context
StockSavvy.ai notes that insider sales, even when conducted under pre-arranged 10b5-1 plans, are routinely monitored by investors for potential signals regarding management's perception of future stock performance. However, 10b5-1 plans are pre-scheduled and often used for personal financial planning, which typically mitigates the immediate read-through as a negative signal compared to unscheduled, discretionary sales.
Stakeholder Impact
- Shareholders: May observe the insider sale, but the 10b5-1 plan context suggests it is not a direct signal of negative company performance.
Key Dates
| Date | Description |
|---|---|
| 09/23/2025 | Date the 10b5-1 trading plan was adopted by Daniel S. Lorrain. |
| 03/02/2026 | Date of the reported transaction (sale of Class A Common Stock). |
Recommendation
holdThe sale by the Chief Scientific Officer was executed under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to manage personal finances. This type of transaction is generally not interpreted as a signal of a change in the company's fundamental outlook and therefore does not warrant a change in investment recommendation based solely on this filing.
Keywords
Contineum Therapeutics, CTNM, Insider Trading, Form 4, Stock Sale, Daniel S. Lorrain, Chief Scientific Officer, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.